Advertisement
Research Article

Clinical Significance of sIL-2R Levels in B-Cell Lymphomas

  • Noriaki Yoshida mail,

    nyoshida@aichi-cc.jp (NY); sakira@fmu.ac.jp (AS)

    Affiliations: Department of Hematology and Oncology, Research Institute Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan, Department of Cancer Genetics, Nagoya University Graduate School of Medicine at Aichi Cancer Center Research Institute, Nagoya, Japan

    X
  • Miyo Oda,

    Affiliation: Department of Anatomical Pathology, Hiroshima University, Hiroshima, Japan

    X
  • Yoshiaki Kuroda,

    Affiliation: Department of Hematology and Oncology, Research Institute Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

    X
  • Yuta Katayama,

    Affiliation: Department of Internal Medicine, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, Japan

    X
  • Yoshiko Okikawa,

    Affiliation: Department of Hematology, National Hospital Organization Kure Medical Center, Kure, Japan

    X
  • Taro Masunari,

    Affiliation: Department of Hematology, Chugoku Central Hospital, Fukuyama, Japan

    X
  • Megumu Fujiwara,

    Affiliation: Department of Pathology, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, Japan

    X
  • Takashi Nishisaka,

    Affiliation: Department of Laboratory Pathology, Hiroshima Prefecture Hospital, Hiroshima, Japan

    X
  • Naomi Sasaki,

    Affiliation: Department of Pathology, Kure Kyosai Hospital, Kure, Japan

    X
  • Yoshito Sadahira,

    Affiliation: Department of Pathology, Kawasaki Medical School, Kurashiki, Japan

    X
  • Keichiro Mihara,

    Affiliation: Department of Hematology and Oncology, Research Institute Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

    X
  • Hideki Asaoku,

    Affiliation: Department of Internal Medicine, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, Japan

    X
  • Hirotaka Matsui,

    Affiliation: Department of Molecular Oncology & Leukemia Program Project, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

    X
  • Masao Seto,

    Affiliations: Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan, Department of Cancer Genetics, Nagoya University Graduate School of Medicine at Aichi Cancer Center Research Institute, Nagoya, Japan

    X
  • Akiro Kimura,

    Affiliations: Department of Hematology and Oncology, Research Institute Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Department of Laboratory medicine, Kure Kyosai Hospital, Kure, Japan

    X
  • Koji Arihiro,

    Affiliation: Department of Anatomical Pathology, Hiroshima University, Hiroshima, Japan

    X
  • Akira Sakai mail

    nyoshida@aichi-cc.jp (NY); sakira@fmu.ac.jp (AS)

    Affiliations: Department of Hematology and Oncology, Research Institute Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Department of Radiation Life Science, Fukushima Medical University, Fukushima, Japan

    X
  • Published: November 13, 2013
  • DOI: 10.1371/journal.pone.0078730

About the Authors

Noriaki Yoshida, Yoshiaki Kuroda, Keichiro Mihara, Akiro Kimura, Akira Sakai
Department of Hematology and Oncology, Research Institute Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
Noriaki Yoshida, Masao Seto
Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan
Noriaki Yoshida, Masao Seto
Department of Cancer Genetics, Nagoya University Graduate School of Medicine at Aichi Cancer Center Research Institute, Nagoya, Japan
Miyo Oda, Koji Arihiro
Department of Anatomical Pathology, Hiroshima University, Hiroshima, Japan
Yuta Katayama, Hideki Asaoku
Department of Internal Medicine, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, Japan
Yoshiko Okikawa
Department of Hematology, National Hospital Organization Kure Medical Center, Kure, Japan
Taro Masunari
Department of Hematology, Chugoku Central Hospital, Fukuyama, Japan
Megumu Fujiwara
Department of Pathology, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, Japan
Takashi Nishisaka
Department of Laboratory Pathology, Hiroshima Prefecture Hospital, Hiroshima, Japan
Naomi Sasaki
Department of Pathology, Kure Kyosai Hospital, Kure, Japan
Yoshito Sadahira
Department of Pathology, Kawasaki Medical School, Kurashiki, Japan
Hirotaka Matsui
Department of Molecular Oncology & Leukemia Program Project, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
Akiro Kimura
Department of Laboratory medicine, Kure Kyosai Hospital, Kure, Japan
Akira Sakai
Department of Radiation Life Science, Fukushima Medical University, Fukushima, Japan

Corresponding Authors

Competing Interests

The authors have declared that no competing interests exist.

Author Contributions

Conceived and designed the experiments: NY HA MS AS. Performed the experiments: NY MO HM KA AS. Analyzed the data: NY TM AS. Contributed reagents/materials/analysis tools: Y. Kuroda Y. Katayama YO TM MF TN NS YS KM HA AS AK. Wrote the paper: NY AS.